Starpharma Holdings Limited · ASX:SPL

Starpharma — Corporate Update (May 2024)

29 slides from Starpharma's corporate update, May 22, 2024

  1. Slide 1: Business Update

    Slide 1: Business Update

    ASX : SPL OTCQX : SPHRY Business Update CEO, Cheryl Maley 22 May 2024 Presented By:

  2. Slide 2: Important Notice and Disclaimer

    Slide 2: Important Notice and Disclaimer

    Important Notice and Disclaimer This document is intended for investors and market participants only. This document contains certain forward-looking statements, relating to Starpharma’s business, which can be identified by the use of forward-looking terminology such as “promising”, “plans”, “anticip

  3. Slide 3: Our Mission

    Slide 3: Our Mission

    “To help patients with significant illness, such as cancer, achieve Our Mission improved health outcomes and quality of life through the application of our unique dendrimer technology.” Presented By: CEO, Cheryl Maley 3

  4. Slide 4: Starpharma Today

    Slide 4: Starpharma Today

    Starpharma Today Corporate Overview Starpharma Value Proposition ASX:SPL Clinically validated technology Ticker Symbol OTCQX: SPHRY More than 350 patients treated with Cash Balance DEP® across multiple clinical programs. A$26.6 M (31 March 2024) Strong intellectual property position 21 active patent

  5. Slide 5: DEP Dendrimers: Versatile, Multifunctional Delivery Platform for Therapies and Diagnostics

    Slide 5: DEP Dendrimers: Versatile, Multifunctional Delivery Platform for Therapies and Diagnostics

    DEP® Dendrimers: Versatile, Multifunctional Delivery Platform for Therapies and Diagnostics Clinically validated platform Commercial Products Starpharma is the only company to More than 350 patients treated have commercialised dendrimer- across multiple clinical programs based products and multiple

  6. Slide 6: Clinician Perspectives on the DEP Platform and Related Clinical Trials

    Slide 6: Clinician Perspectives on the DEP Platform and Related Clinical Trials

    Clinician Perspectives on the DEP® Platform and Related Clinical Trials Presented By: CEO, Cheryl Maley 6

  7. Slide 7: Key Insights from the Business Review

    Slide 7: Key Insights from the Business Review

    Key Insights from the Business Review Portfolio Shareholders Operations Partners Capability • Broad portfolio and • Strong belief in the • Opportunity to • Extremely positive • Unique strength and optionality - previous value of the strengthen plan feedback – SPL is very broad strengths, but may den

  8. Slide 8: Our Strategy

    Slide 8: Our Strategy

    Our Strategy Starpharma, refocused Drive growth and shareholder value through clear prioritisation and a clear focus on delivery and execution. Presented By: CEO, Cheryl Maley 8

  9. Slide 9: Starpharma, Refocused

    Slide 9: Starpharma, Refocused

    Starpharma, Refocused Three key focus areas to optimise shareholder returns 01 02 03 Maximise DEP® Accelerate early Build long-term asset value asset sustainability development Presented By: CEO, Cheryl Maley 9

  10. Slide 10: Starpharma, Refocused

    Slide 10: Starpharma, Refocused

    Starpharma, Refocused Three key focus areas to optimise shareholder returns 01 02 03 Maximise DEP® Accelerate early Build long-term asset value asset sustainability development Presented By: CEO, Cheryl Maley 10

  11. Slide 11: Maximise DEP Asset Value

    Slide 11: Maximise DEP Asset Value

    Maximise DEP® Asset Value What has changed? Key objective: • DEP® asset and Successfully convert priority indication prioritisation opportunities to license deals • Enhanced BD capability (internal and external) Key priorities: KPIs 1. Signing partnership deals for priority assets, DEP® irinotecan •

  12. Slide 12: Current DEP Portfolio and Next Steps

    Slide 12: Current DEP Portfolio and Next Steps

    Current DEP® Portfolio and Next Steps Target Product Research Pre-clinical Phase 1 Phase 2 Goal / Next Steps indication Prostate and DEP® cabazitaxel Phase 2 complete & results reported License – Prostate, Ovarian other cancers Colorectal and Phase 2 recruitment complete & results to be reported DEP

  13. Slide 13: DEP Clinical Assets Offer a De-risked Development Program with an Established Market Opportunity

    Slide 13: DEP Clinical Assets Offer a De-risked Development Program with an Established Market Opportunity

    DEP® Clinical Assets Offer a De-risked Development Program with an Established Market Opportunity Chemotherapies remain standard-of- DEP® delivery improved tolerability and Demonstrated ability to overcome care and form the backbone of anticancer efficacy in multiple anticancer treatment resistance

  14. Slide 14: Partner for DEP Clinical Assets

    Slide 14: Partner for DEP Clinical Assets

    Partner for DEP® Clinical Assets Potential deal structures Big Pharma or Mid-Tier or Specialty Pharma Regional Country Global e.g. EU/North America e.g. China, Japan • Single partner - • Core expertise in regional • Country-centric development one commercialisation plan regulatory guidelines and com

  15. Slide 15: DEP Dendrimers: Bridging the Gap for Precision Cancer Radiopharmaceuticals

    Slide 15: DEP Dendrimers: Bridging the Gap for Precision Cancer Radiopharmaceuticals

    DEP® Dendrimers: Bridging the Gap for Precision Cancer Radiopharmaceuticals Radiopharmaceuticals help realise the potential of personalised medicine through achieving selective and targeted precision tailored to a patient’s Why we’re targeting HER2+ specific disease or biological target cancers • HE

  16. Slide 16: Radiopharmaceuticals and ADC Development Update

    Slide 16: Radiopharmaceuticals and ADC Development Update

    Radiopharmaceuticals and ADC Development Update DEP® Radiopharmaceuticals DEP® Antibody-drug Conjugates DEP® HER2-radiodiagnostic DEP® HER2-radiotherapy DEP® HER2-ADC For whole-body localisation of HER2+ For targeted treatment of HER2+ For targeted treatment of HER2+ tumours tumours, to aid in diagn

  17. Slide 17: Starpharma, Refocused

    Slide 17: Starpharma, Refocused

    Starpharma, Refocused Three key focus areas to optimise shareholder returns 01 02 03 Maximise DEP® Accelerate early Build long-term asset value asset sustainability development Presented By: CEO, Cheryl Maley 17

  18. Slide 18: Accelerate Early Asset Development

    Slide 18: Accelerate Early Asset Development

    01 Accelerate Early Asset Development Key objectives: What is changing? • Increase # assets in early • Approach to asset candidate development identification • Increase efficiency of early • Models for partner engagement development • Pace of development Key priorities: KPIs • Advance Genentech and

  19. Slide 19: Accelerate Early Asset Development

    Slide 19: Accelerate Early Asset Development

    Accelerate Early Asset Development Increasing collaboration opportunities with the aim of successfully progressing through to partnering for value creation (e.g., development, commercialisation or asset sale) DEP® Clinical Assets RESEARCH DEVELOPMENT COMMERCIALISATION SPL Value Creation Presented By

  20. Slide 20: Early-Stage Partnerships / Collaborations

    Slide 20: Early-Stage Partnerships / Collaborations

    Early-Stage Partnerships / Collaborations R&D collaboration Oncology/non-Oncology Types of ADCs Partnerships Co-development Therapeutic Radiotheranostics and Applications Collaboration Licence Drug Rescue Opportunities NCE Development Technology access Patent Extension Current Active Partnerships Pr

  21. Slide 21: Our Strategic Partnership with Medicxi

    Slide 21: Our Strategic Partnership with Medicxi

    Our Strategic Partnership with Medicxi is a leading healthcare investment firm with a track record of success, and a partner of choice for the development and commercialisation of novel therapies using Starpharma’s dendrimer technology Recap of the partnership Why this is important for SPL now • Med

  22. Slide 22: Starpharma, Refocused

    Slide 22: Starpharma, Refocused

    Starpharma, Refocused Three key focus areas to optimise shareholder returns 01 02 03 Maximise DEP® Accelerate early Build long-term Asset Value asset sustainability development Presented By: CEO, Cheryl Maley 22

  23. Slide 23: Build Long-term Sustainability

    Slide 23: Build Long-term Sustainability

    01 Build Long-term Sustainability Key objectives: What is changing? • Build revenue and manage costs • Digital consumer strategy for • Create a self-sustaining Viraleze in the UK and Europe organisation • Address capability gaps Key priorities: • License revenue KPIs • Digital marketing capability t

  24. Slide 24: Increase VivaGel BV and Viraleze Revenue

    Slide 24: Increase VivaGel BV and Viraleze Revenue

    Increase VivaGel® BV and Viraleze Revenue VivaGel® BV Viraleze • Registered in more than 40 jurisdictions, • Registered in more than 35 jurisdictions*, including in the UK, Europe, Southeast Asia, including in Europe, the UK, and Asia. South Africa, Australia and New Zealand. • Awaiting TGA outcome.

  25. Slide 25: Build Long-term Sustainability

    Slide 25: Build Long-term Sustainability

    Build Long-term Sustainability Intellectual Financials People ESG Property • Increase • Enhance • Protect • Environmental revenue: performance background IP impact licensing, culture for DEP® • Society / Viraleze and • Address • Continue to patient impact VivaGel® sales capability gaps generate new

  26. Slide 26: Short- and Medium-Term Priorities

    Slide 26: Short- and Medium-Term Priorities

    Short- and Medium-Term Priorities Our Immediate Short Medium Approach 0 – 9 months 9 – 18 months 18 – 24 months License DEP® asset/s Radio and ADC Development Radiotheranostic collaboration Maximise DEP® asset value Advance radiodiagnostic New collaborations New collaborations Accelerate early asset

  27. Slide 27: Leadership Team For Q&A Session

    Slide 27: Leadership Team For Q&A Session

    Leadership Team For Q&A Session Cheryl Maley, BSc, DipEd, MBA, Justin Cahill, BBus, MPA, CPA Jeremy Paull, BSc (Hons), PhD Tony Eglezos, BSc (Hons), GAICD Chief Financial Officer and Company Vice President, Development and PhD, MBA Chief Executive Officer and Managing Secretary Regulatory Affairs Vi

  28. Slide 28: Q&A

    Slide 28: Q&A

    Q&A Presented By: CEO, Cheryl Maley 28

  29. Slide 29: Thank you.

    Slide 29: Thank you.

    ASX : SPL OTCQX : SPHRY Thank you. Investor Relations Corporate Office Investor.Relations@Starpharma.com.au 4 – 6 Southampton Crescent Abbotsford, Victoria 3067 Australia Presented By:

Source: Internet Archive copy of archive.starpharma.com

More decks from Starpharma Holdings Limited

All 67 Starpharma decks